Monday, March 3, 2025 – Many people who have tried to lose weight by cutting calories are familiar with this frustrating reality: At some point, the body stops shedding pounds. It senses the reduced calorie intake and responds by slowing down metabolism, causing it to burn fewer calories than before the diet.
Monday, March 3, 2025 – Semaglutide, a GLP-1 receptor agonist initially approved for type 2 diabetes and later for weight management, is now showing potential in treating ...
Monday, March 3, 2025 – Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is an injectable prescription medicine used: along with diet and exercise to improve blood ...
Monday, March 3, 2025 – Numerous studies have shown that a diet high in sugar and fat — a so-called “Western-style diet” — is linked to colorectal cancer, as well as obesity ...
Monday, March 3, 2025 – ... obesity and diabetes in the region. This chronic liver condition can lead to serious health conditions including severe liver fibrosis or ...
Monday, March 3, 2025 – Eli Lilly wants to replace Zepbound with an even stronger weight loss drug. Nvidia's record earnings reveal just 3 customers make up 30% of revenue.
Monday, March 3, 2025 – Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used primarily for the treatment of type 2 diabetes and obesity. The growing ...
Monday, March 3, 2025 – ... cancer, obesity, and cardiovascular diseases. North America has a ... Obesity is a primary application area for nutrigenomics. The obesity ...
Monday, March 3, 2025 – The Awareness, Care, and Treatment in Obesity maNagement in the Asia Pacific region ... 79%), cancer (72% vs. 68%), or stroke (68% vs. 74%) (Fig ...
Monday, March 3, 2025 – Many employers and insurers are scaling back coverage of Wegovy and Zepbound, and a key government program, Medicare, doesn't cover the drugs for ...